Molecularly-targeted agents, such as midostaurin for FLT3+ patients and enasidenib for patients with isocitrate dehydrogenase-2 (IDH2) mutations, have been approved by the U.S. Food and Drug Administration in 2017 for use in patients with relapsed/refractory AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.